GILD vs NBIX
Gilead Sciences, Inc. and Neurocrine Biosciences Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | GILD | NBIX |
|---|---|---|
| Revenue | $29.4B | $2.9B |
| Net income | $8.5B | $478.6M |
| Gross margin | 78.8% | 98.2% |
| Net margin | 28.9% | 16.7% |
| Return on equity | 40.5% | 16.4% |
| Diluted EPS | $6.78 | $4.67 |
| Dividend / share | $3.16 | · |
| Payout ratio | 47.0% | · |
| Free cash flow | $9.5B | $748.7M |
| Equity | $22.7B | $3.3B |
| Net debt / equity | 0.77× | · |
| Current ratio | 1.55× | 3.39× |
| Revenue CAGR 5y | 3.6% | 22.3% |
| Profit CAGR 5y | 133.3% | 3.3% |
GILD bills 10.3× the revenue of NBIX, and keeps more of each dollar of revenue as profit (28.9% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | GILD | NBIX |
|---|---|---|
| FY2025 | $29.4B | $2.9B |
| FY2024 | $28.8B | $2.4B |
| FY2023 | $27.1B | $1.9B |
| FY2022 | $27.3B | $1.5B |
| FY2021 | $27.3B | $1.1B |
| FY2020 | $24.7B | $1.0B |
| FY2019 | $22.4B | $788.1M |
| FY2018 | $22.1B | $451.2M |
| FY2017 | $26.1B | $161.6M |
| FY2016 | $30.4B | $15.0M |
Bottom line
| Fiscal year | GILD | NBIX |
|---|---|---|
| FY2025 | $8.5B | $478.6M |
| FY2024 | $480.0M | $341.3M |
| FY2023 | $5.7B | $249.7M |
| FY2022 | $4.6B | $154.5M |
| FY2021 | $6.2B | $89.6M |
| FY2020 | $123.0M | $407.3M |
| FY2019 | $5.4B | $37.0M |
| FY2018 | $5.5B | $21.1M |
| FY2017 | $4.6B | $-142.5M |
| FY2016 | $13.5B | $-141.1M |
17 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$26,582,500,000 | GILD |
| FY2024 | +$26,398,700,000 | GILD |
| FY2023 | +$25,228,900,000 | GILD |
| FY2022 | +$25,792,300,000 | GILD |
| FY2021 | +$26,171,500,000 | GILD |
| FY2020 | +$23,643,100,000 | GILD |
| FY2019 | +$21,660,900,000 | GILD |
| FY2018 | +$21,675,800,000 | GILD |
| FY2017 | +$25,945,374,000 | GILD |
| FY2016 | +$30,375,000,000 | GILD |
| FY2015 | +$32,619,231,000 | GILD |
| FY2014 | +$24,890,000,000 | GILD |
| FY2013 | +$11,199,081,000 | GILD |
| FY2012 | +$9,648,860,000 | GILD |
| FY2011 | +$8,307,972,000 | GILD |
| FY2010 | +$7,915,919,000 | GILD |
| FY2009 | +$7,008,430,000 | GILD |
GILD has reported the higher revenue in every one of these 17 fiscal years. The gap has widened since the earliest year compared.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.
14 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +12.2 pp | GILD |
| FY2024 | −12.8 pp | NBIX |
| FY2023 | +7.5 pp | GILD |
| FY2022 | +6.4 pp | GILD |
| FY2021 | +14.8 pp | GILD |
| FY2020 | −38.6 pp | NBIX |
| FY2019 | +19.2 pp | GILD |
| FY2018 | +20.0 pp | GILD |
| FY2017 | +106.0 pp | GILD |
| FY2016 | +985.0 pp | GILD |
| FY2015 | +505.3 pp | GILD |
| FY2012 | +17.1 pp | GILD |
| FY2011 | −15.3 pp | NBIX |
| FY2010 | +60.1 pp | GILD |
The higher net margin has changed hands between GILD and NBIX over this period.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's net margin has been more volatile than GILD's over the 14 comparable fiscal years — 263.7 percentage points of standard deviation against 14.2.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between GILD and NBIX over these 14 fiscal years — GILD led in 11 and NBIX in 3.
14 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
NBIX's return on equity has been more volatile than GILD's over the 17 comparable fiscal years — 305.5 percentage points of standard deviation against 27.2.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between GILD and NBIX over these 17 fiscal years — GILD led in 14 and NBIX in 3.
17 of 19 comparable fiscal years — a year missing data on either side is not counted.